News coverage

Dr Marlyn Mayo and Dr Andreas Kremer share key insights on primary sclerosing cholangitis from AASLD The Liver Meeting 2025, and explore the latest in therapeutic developments and symptomatology.

Dr Silvia Vilarinho and Dr Deepak Joshi share the highlights from AASLD The Liver Meeting 2025, with an emphasis on late-onset genetic cholestasis, and offer quick insights into new data on the growing utility of genetic testing and expanding therapeutic implications.

Dr Andreas Kremer and Dr Marlyn Mayo highlight key advances in primary biliary cholangitis from AASLD The Liver Meeting 2025, and provide quick insights into the latest data on next-generation therapies.

Marlyn Mayo reviews RESPONSE analyses on seladelpar symptom effects in PBC.

Marlyn Mayo discusses findings on physician attitudes to managing pruritus in PSC.

Giving seladelpar beyond 12 months offers primary biliary cholangitis patients improvements in pruritus and biochemical markers, show ongoing analyses.

A real-world analysis of PSC patients given maralixibat suggests it offers meaningful improvements in pruritus.

Most cases of unexplained cholestasis in adults have an identifiable underlying genetic cause.

Adults living with unexplained cholestasis could receive a diagnosis with next generation sequencing, suggests US study.

Marios Nikolaidis shares findings on the gut microbiome in PSC management.

A mind–body intervention accessed online may help patients with liver disease better manage their symptoms.

An analysis of trial data indicates that, alongside reducing pruritus, volixibat helps normalize fatigue and sleep in PBC patients.

A large US gene panel has helped to elucidate the underlying genetic basis of unexplained cholestasis.

Mitchell Shiffman discusses the value of genetic testing in adults with undefined cholestasis.

Mitchell Shiffman comments on ELMWOOD findings for elafibranor in PSC.

A correlation between PRO-C3 and liver measures in PBC suggests it could represent a novel disease biomarker.

ELATIVE open-label extension trial findings support long-term elafibranor treatment in patients with PBC.

US researchers have found that the numerous and potentially distressing symptoms of PSC fit into four clear profiles.

Natural language programming could help identify which adults with cholestasis have late-onset progressive familial intrahepatic cholestasis.

Andreas Kremer explains post-hoc analysis findings from the phase 3 GLISTEN trial showing an effect of linerixibat on biomarkers and mediators of pruritus in patients with PBC.

Discussing the ASSURE findings for seladelpar in PBC with Daniel Pratt.

Mark Swain on 3-year elafibranor benefits, proteomics in PBC.

Natural language programming could help identify which adults with cholestasis have late-onset progressive familial intrahepatic cholestasis.

Real-world evidence supports seladelpar use in patients with PBC initiating seladelpar second-line or switching from obeticholic acid.

Treatment-refractory pruritus following liver transplant may be successfully treated with IBAT inhibitors, suggests a US case series.

An open-label trial extension showed that the PPAR agonist elafibranor maintained efficacy, and former placebo patients saw improvements.

Raj Vuppalanchi reports findings characterizing the phenotype of women with hormonal contraceptive-associated drug-induced liver injury.

Andreas Kremer discusses post-hoc analyses from the ELATIVE trial showing independent improvement in patient-reported outcomes with elafibranor for patients with PBC and efficacy irrespective of BMI.

Dr Marlyn Mayo and Dr Andreas Kremer discuss what’s ahead at AASLD 2025, with a focus on advances in primary biliary cholangitis and primary sclerosing cholangitis. They share their perspectives on emerging research, key topics to watch, and what they are most looking forward to at this year’s meeting.

Dr Deepak Joshi and Dr Silvia Vilarinho discuss what’s ahead at AASLD 2025, focusing on late-onset genetic cholestasis and Alagille syndrome, and share what they are most looking forward to at this year’s meeting.

Dr Marlyn Mayo and Dr Andreas Kremer discuss what’s ahead at AASLD 2025, with a focus on advances in primary biliary cholangitis and primary sclerosing cholangitis. They share their perspectives on emerging research, key topics to watch, and what they are most looking forward to at this year’s meeting.

Ileal bile acid transporter inhibitors help treat adults with drug-induced or pregnancy-related intrahepatic cholestasis

Dr Richard Thompson and Dr Verena Keitel-Anselmino discuss the latest updates on IBAT inhibitors from EASL 2025, including their potential use in PBC patients based on promising phase I and II trial results.

Preclinical findings at EASL Congress 2025 point to organoid models for different types of PFIC.

Research confirms that the EASL guidelines aid risk stratification for intrahepatic cholestasis of pregnancy.

Research shows the utility of genetic testing for patients with adult-onset cholestatic disease.

Drs Richard Thompson and Verena Keitel-Anselmino discuss their cholestasis preclinical highlights from the EASL Congress 2025.

Ms Nina Rodriguez and Dr Tatyana Kushner confirm that the 2023 EASL guidelines can help risk stratify patients with intrahepatic cholestasis of pregnancy.

Research sheds light on the varying impact of ABCB4 gene variants in intrahepatic cholestasis of pregnancy and other adult-onset forms of cholestasis.

Updated results for adult participants of the PEDFIC2 trial and older children taking part in the ASSERT-EXT study.

Case studies demonstrate the utility of genetic analysis and whole-exome sequencing for the diagnosis of progressive familial intrahepatic cholestasis in patients with nonspecific liver disease.

Stay up to date with the latest in Primary Biliary Cholangitis with downloadable summaries of key trials from the 2024 AASLD Liver Meeting.

Further findings on the efficacy and safety of ileal bile acid transporter inhibitors for patients with progressive familial intrahepatic cholestasis have been presented at the 2024 AASLD The Liver Meeting in San Diego, California, USA.

Dr Miki Scaravaglio talks through her proof-of-principle study findings for use of whole-exome sequencing to aid the diagnosis of people with adult-onset cholestatic liver disease.

Whole-exome sequencing led to definitive diagnoses for almost a quarter of patients with unexplained adult-onset cholestatic liver disease, say Italian researchers.

Dr Andrew Stolz reports on the relationship between alterations to the ABCB11 gene and the risk of drug-induced liver injury from anabolic steroids.

Professor Richard Thompson shares his PFIC poster findings on the long-term efficacy and safety data of the PEDFIC 2 trial and the relationship between serum bile acid and event-free survival in the MARCH and MARCH-ON trials.

Alterations to ABCB11 play a “pivotal role” in the development of drug-induced liver injury from anabolic steroids, US researchers reported at the 2024 AASLD The Liver Meeting in San Diego, California, USA.

Trial findings suggest that the IBAT inhibitor odevixibat does not prevent absorption of combined oral contraceptives in healthy women.

An EASL expert panel has developed clinical practice guidelines for the management of progressive familial intrahepatic cholestasis and other genetic cholestatic liver diseases.

Dr Adriaan Van der Meer shares his insights on the results from the combination trial of obeticholic acid and bezafibrate for PBC patients, presented at EASL 2024 in Milan, Italy. In addition, discover key findings and learn about the RECAPITULATE trial, focusing on real-world treatment outcomes.

Professor Mark Swain discusses the latest updates from the ASSURE trial of seladelpar, presented at EASL 2024, in Milan, Italy. Explore key findings on efficacy, safety, and interim long-term results of this study.

Professor Marco Carbone reviews the latest updates from the ELATIVE trial of elafibranor, presented at EASL 2024 in Milan, Italy. Discover key insights on efficacy, quality of life improvements, and the broader significance of these results.

ASSURE study findings show that seladelapr elicits a biochemical response in patients with primary biliary cholangitis and cirrhosis.

ELATIVE subanalysis confirms improved biochemical response with elafibranor over placebo for primary biliary cholangitis according to various different criteria.

Combining slow-release bezafibrate with obeticholic acid shows treatment potential for patients with primary biliary cholangitis.

ELATIVE trial results for pruritus show benefits for both severity and impact on the quality of life of patients with primary biliary cholangitis.

Prof. Andreas Kremer provides his insights on studies on second-line obeticholic acid presented at The Liver Meeting 2023: its use in a real-world setting and as combination therapy with bezafibrate.

Dr Kris Kowdley comments on some of the key data in primary biliary cholangitis, presented at The Liver Meeting 2023, including the ELATIVE trial involving elafibranor.

Dr Gideon Hirschfield discusses some of the highlights on primary biliary cholangitis from The Liver Meeting 2023, with a focus on the RESPONSE trial of seladelpar.

Obeticholic acid positively affects liver function among patients with primary biliary cholangitis in the second-line treatment setting.

ELATIVE trial shows that elafibranor significantly improves biochemical response in patients with primary biliary cholangitis with anti-pruritic benefits.

RESPONSE trial findings show seladelpar improves markers of disease activity and reduces pruritus in patients with primary biliary cholangitis.

Denosumab is comparable to bisphosphonates for treating osteoporosis in patients with primary biliary cholangitis, but with fewer adverse effects.

Combining obeticholic acid with bezafibrate 400 mg/day shows therapeutic potential in patients with primary biliary cholangitis in two phase 2 trials.